Epithelial plasticity in prostate cancer: Principles and clinical perspectives

Trends in Molecular Medicine

Volumn 20, Issue 11, 2014, Pages 643-651

  Das, Rajdeep ^a   Gregory, Philip A ^a,b   Hollier, Brett G ^c   Tilley, Wayne D ^a   Selth, Luke A ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Androgen deprivation therapy; Androgen receptor; Chemotherapy; Epithelial plasticity; Epithelial mesenchymal transition; Mesenchymal epithelial transition

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CELL INTERACTION; CELL TRANSFORMATION; CLINICAL FEATURE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIAL PLASTICITY; EVIDENCE BASED PRACTICE; HUMAN; LETHALITY; MALE; METASTASIS POTENTIAL; MULTIMODALITY CANCER THERAPY; NONHUMAN; PROSTATE CANCER; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; DISEASE COURSE; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS;

DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84909589374     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.09.004     Document Type: Review

References (93)

1. Siegel R., et al. Cancer statistics, 2012. CA 2012, 62:10-29.
2. Shah R.B., et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004, 64:9209-9216.
3. Asmane I., et al. New strategies for medical management of castration-resistant prostate cancer. Oncology 2011, 80:1-11.
4. Rescigno P., et al. New perspectives in the therapy of castration resistant prostate cancer. Curr. Drug Targets 2012, 13:1676-1686.
5. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
6. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
7. Rubin M.A., et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum. Pathol. 2001, 32:690-697.
8. Nieto M.A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013, 342:1234850. 10.1126/science.1234850.
9. Banyard J., et al. Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci. Rep. 2013, 3:3151. 10.1038/srep03151.
10. Celia-Terrassa T., et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 2012, 122:1849-1868.
11. Korpal M., et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17:1101-1108.
12. Ocana O.H., et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
13. Tsai J.H., et al. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22:725-736.
14. Tsuji T., et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 2008, 68:10377-10386.
15. Mani S.A., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
16. Kong D., et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS ONE 2010, 5:e12445.
17. Albino D., et al. ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features. Cancer Res. 2012, 72:2889-2900.
18. Giannoni E., et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010, 70:6945-6956.
19. Armstrong A.J., et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol. Cancer Res. 2011, 9:997-1007.
20. Chen C.L., et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 2013, 73:813-826.
21. Friedlander T.W., et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int. J. Cancer 2014, 134:2284-2293.
22. Gorges T.M., et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012, 12:1-13.
23. Gravdal K., et al. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin. Cancer Res. 2007, 13:7003-7011.
24. Sethi S., et al. Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am. J. Transl. Res. 2010, 3:90-99.
25. Jennbacken K., et al. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 2010, 17:469-479.
26. Tanaka H., et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat. Med. 2010, 16:1414-1420.
27. Domingo-Domenech J., et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22:373-388.
28. Bitting R.L., et al. The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev. 2014, 33:441-468.
29. Li P., et al. Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol. Cancer 2014, 13:55.
30. Oltean S., et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14116-14121.
31. Chao Y., et al. Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin. Exp. Metastasis 2012, 29:39-50.
32. Josson S., et al. Tumor-stromal interactions influence radiation sensitivity in epithelial- versus mesenchymal-like prostate cancer cells. J. Oncol. 2010, 10.1155/2010/232831.
33. Brase J.C., et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 2011, 128:608-616.
34. Selth L.A., et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br. J. Cancer 2013, 109:641-650.
35. Bryant R.J., et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 2012, 106:768-774.
36. Selth L.A., et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int. J. Cancer 2012, 131:652-661.
37. Madhavan D., et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 2012, 18:5972-5982.
38. Pattabiraman D.R., Weinberg R.A. Tackling the cancer stem cells - what challenges do they pose?. Nat. Rev. Drug Discov. 2014, 13:497-512.
39. Bae K.M., et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J. Urol. 2010, 183:2045-2053.
40. Yan H., et al. Drug-tolerant cancer cells show reduced tumor-initiating capacity: depletion of CD44 cells and evidence for epigenetic mechanisms. PLoS ONE 2011, 6:e24397.
41. Li R., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010, 7:51-63.
42. Redmer T., et al. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. EMBO Rep. 2011, 12:720-726.
43. Shamir E.R., et al. Twist1-induced dissemination preserves epithelial identity and requires E-cadherin. J. Cell Biol. 2014, 204:839-856.
44. Murashima A., et al. Androgens and mammalian male reproductive tract development. Biochim. Biophys. Acta 2014, 10.1016/j.bbagrm.2014.05.020.
45. Hara T., et al. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008, 68:1128-1135.
46. Anose B.M., Sanders M.M. Androgen receptor regulates transcription of the ZEB1 transcription factor. Int. J. Endocrinol. 2011, 2011:10.
47. Wu K., et al. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol. Endocrinol. 2012, 26:1496-1507.
48. Jin H.J., et al. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Cancer Res. 2013, 73:3725-3736.
49. Jing Y., et al. Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. Cancer Lett. 2014, 348:135-145.
50. Graham T.R., et al. Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res. Treat. 2010, 123:139-147.
51. Lee Y.C., et al. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J. Pathol. 2010, 221:68-76.
52. Sun Y., et al. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res. 2012, 72:527-536.
53. Izumi K., et al. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol. Med. 2013, 5:1383-1401.
54. Schroeder A., et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014, 74:1227-1237.
55. Wan X., et al. Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin. Cancer Res. 2012, 18:726-736.
56. Song K., et al. DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Mol. Endocrinol. 2010, 24:2019-2029.
57. Shiota M., et al. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer. Clin. Cancer Res. 2014, 20:951-961.
58. Alonso-Magdalena P., et al. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2859-2863.
59. Eide T., et al. TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells. Cancer Cell Int. 2013, 13:4.
60. Chan S.C., Dehm S.M. Constitutive activity of the androgen receptor. Adv. Pharmacol. 2014, 70:327-366.
61. Cottard F., et al. Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS ONE 2013, 8:e63466.
62. Liu G., et al. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 2013, 15:1009-1017.
63. Sun F., et al. Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J. Biol. Chem. 2014, 289:1529-1539.
64. Becker-Santos D.D., et al. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis 2012, 33:2558-2567.
65. Gupta S., et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2010, 70:6735-6745.
66. Leshem O., et al. TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model. PLoS ONE 2011, 6:e21650.
67. Kim J., et al. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene 2013, 10.1038/onc.2013.461.
68. Zhu M.L., Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2010, 24:769-777.
69. Armstrong A.J., et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur. Urol. 2012, 61:549-559.
70. Marin-Aguilera M., et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol. Cancer Ther. 2014, 10.1158/1535-7163.MCT-13-0775.
71. Puhr M., et al. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am. J. Pathol. 2012, 181:2188-2201.
72. Kim J.J., et al. Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer. J. Cell. Biochem. 2013, 114:1286-1293.
73. Chang L., et al. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013, 4:e875.
74. Sun Y., et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat. Med. 2012, 18:1359-1368.
75. Kahn B., et al. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int. J. Biol. Sci. 2014, 10:588-595.
76. Goldstein A.S., et al. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
77. Josson S., et al. beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res. 2011, 71:2600-2610.
78. Morgan T.M., et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin. Cancer Res. 2009, 15:677-683.
79. Smith A.L., et al. Molecular pathways: targeting the TGF-beta pathway for cancer therapy. Clin. Cancer Res. 2012, 18:4514-4521.
80. Iinuma H., et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J. Clin. Oncol. 2011, 29:1547-1555.
81. Miyamoto D.T., et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012, 2:995-1003.
82. Brabletz T., et al. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005, 5:744-749.
83. Brabletz T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 2012, 12:425-436.
84. Klein C.A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 2009, 9:302-312.
85. Amatangelo M.D., et al. c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer. Carcinogenesis 2012, 33:1965-1975.
86. Terry S., Beltran H. The many faces of neuroendocrine differentiation in prostate cancer progression. Front. Oncol. 2014, 4:60.
87. Aparicio A.M., et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 2013, 19:3621-3630.
88. Yu X., et al. Wnt/beta-catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2011, 30:1868-1879.
89. McKeithen D., et al. Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010, 70:982-992.
90. Salvatori L., et al. Cell-to-cell signaling influences the fate of prostate cancer stem cells and their potential to generate more aggressive tumors. PLoS ONE 2012, 7:e31467.
91. Sotomayor P., et al. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009, 69:401-410.
92. Beltran H., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011, 1:487-495.
93. Slattum G.M., Rosenblatt J. Tumour cell invasion: an emerging role for basal epithelial cell extrusion. Nat. Rev. Cancer 2014, 14:495-501.